XNASDBVT
Market cap66mUSD
Dec 24, Last price
3.04USD
1D
-7.74%
1Q
334.29%
Jan 2017
-91.35%
IPO
-86.72%
Name
Dbv Technologies SA
Chart & Performance
Profile
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 15,728 227.67% | 4,800 -15.91% | 5,708 -49.38% | |||||||
Cost of revenue | 83,100 | 122,734 | 116,204 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (67,372) | (117,934) | (110,496) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 7 | 100 | (381) | |||||||
Tax Rate | ||||||||||
NOPAT | (67,379) | (118,034) | (110,115) | |||||||
Net income | (72,726) -24.48% | (96,300) -1.54% | (97,809) -38.70% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 6,767 | 194,594 | 978 | |||||||
BB yield | -79.94% | -0.58% | ||||||||
Debt | ||||||||||
Debt current | 2,027 | 8,897 | 11,546 | |||||||
Long-term debt | 10,196 | 4,148 | 17,297 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 934 | 21,417 | 8,905 | |||||||
Net debt | (132,828) | (200,206) | (52,427) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (79,653) | (55,700) | (108,242) | |||||||
CAPEX | (677) | (754) | (918) | |||||||
Cash from investing activities | (808) | (100) | (433) | |||||||
Cash from financing activities | 6,767 | 194,100 | 274 | |||||||
FCF | (67,639) | (110,161) | (100,700) | |||||||
Balance | ||||||||||
Cash | 141,367 | 209,200 | 77,301 | |||||||
Long term investments | 3,684 | 4,051 | 3,969 | |||||||
Excess cash | 144,265 | 213,011 | 80,985 | |||||||
Stockholders' equity | (236,019) | (262,658) | (257,608) | |||||||
Invested Capital | 383,692 | 488,465 | 384,298 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 77,380 | 54,920 | ||||||||
Price | 1.85 -41.20% | 3.15 2.84% | 3.06 -29.45% | |||||||
Market cap | 243,437 44.90% | 168,000 -28.37% | ||||||||
EV | 43,231 | 115,573 | ||||||||
EBITDA | (81,370) | (104,772) | (102,120) | |||||||
EV/EBITDA | ||||||||||
Interest | 427 | 690 | ||||||||
Interest/NOPBT |